Business Description
Penumbra Inc
NAICS : 339999
SIC : 3841
ISIN : US70975L1070
Total Employee Number:
4,700Description
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.85 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | 0.98 | |||||
Interest Coverage | 143.18 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 19.59 | |||||
Beneish M-Score | -2.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.9 | |||||
3-Year EBITDA Growth Rate | 93.1 | |||||
3-Year EPS without NRI Growth Rate | 188.4 | |||||
3-Year Book Growth Rate | 11.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 25.83 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.32 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
12-1 Month Momentum % | -2.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.02 | |||||
Quick Ratio | 3.95 | |||||
Cash Ratio | 2.91 | |||||
Days Inventory | 330.27 | |||||
Days Sales Outstanding | 45.19 | |||||
Days Payable | 25.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | 0.05 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 67.39 | |||||
Operating Margin % | 12.87 | |||||
Net Margin % | 11.76 | |||||
EBITDA Margin % | 15.22 | |||||
FCF Margin % | 14.52 | |||||
OCF Margin % | 18.92 | |||||
ROE % | 12.64 | |||||
ROA % | 9.79 | |||||
ROIC % | 14.34 | |||||
ROC (Joel Greenblatt) % | 25.76 | |||||
ROCE % | 13 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 72.96 | |||||
Forward PE Ratio | 55.09 | |||||
PE Ratio without NRI | 78.57 | |||||
Shiller PE Ratio | 303 | |||||
Price-to-Owner-Earnings | 65.7 | |||||
PS Ratio | 8.57 | |||||
PB Ratio | 8.45 | |||||
Price-to-Tangible-Book | 9.57 | |||||
Price-to-Free-Cash-Flow | 58.66 | |||||
Price-to-Operating-Cash-Flow | 45.1 | |||||
EV-to-EBIT | 59.01 | |||||
EV-to-Forward-EBIT | 44.17 | |||||
EV-to-EBITDA | 54.47 | |||||
EV-to-Forward-EBITDA | 40.2 | |||||
EV-to-Revenue | 8.29 | |||||
EV-to-Forward-Revenue | 6.79 | |||||
EV-to-FCF | 56.66 | |||||
Price-to-GF-Value | 0.96 | |||||
Price-to-Projected-FCF | 6.39 | |||||
Price-to-Median-PS-Value | 0.81 | |||||
Price-to-Graham-Number | 5.78 | |||||
| Price-to-Net-Current-Asset-Value | 14.64 | |||||
| Price-to-Net-Cash | 65.15 | |||||
Earnings Yield (Greenblatt) % | 1.69 | |||||
FCF Yield % | 1.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Penumbra Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 26,634.39 | ||
| EPS (TTM) (MXN) | 79.749 | ||
| Beta | 0.2211 | ||
| 3-Year Sharpe Ratio | -0.44 | ||
| 3-Year Sortino Ratio | -0.57 | ||
| Volatility % | 2.77 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | 0.000007 | ||
| 20-Day SMA (MXN) | 4775.7 | ||
| 12-1 Month Momentum % | -2.77 | ||
| 52-Week Range (MXN) | 4775.7 - 4911.82 | ||
| Shares Outstanding (Mil) | 39.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Penumbra Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Penumbra Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 130 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 129 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 16:30 | In 31 days | ||
| Second quarter earnings results for 2026 | 2026-07-29 | In 30 days | ||
| General meeting for 2026 | 2026-06-18 11:00 | 4,775.70 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 4,775.70 (+0.00%) | ||
| Annual report for 2025 | 2026-02-25 | 4,775.70 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-25 | 4,775.70 (+0.00%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-12 18:45 | 4,775.70 (+0.00%) | ||
| Piper Sandler 37th Annual Healthcare Conference | 2025-12-03 08:00 | 4,775.70 (+0.00%) |
Show
Entries
Penumbra Inc Frequently Asked Questions
What is Penumbra Inc(MEX:PEN)'s stock price today?
The current price of MEX:PEN is MXN4775.70. The 52 week high of MEX:PEN is MXN4911.82 and 52 week low is MXN4775.70.
When is next earnings date of Penumbra Inc(MEX:PEN)?
The next earnings date of Penumbra Inc(MEX:PEN) is 2026-07-29 Est..
Does Penumbra Inc(MEX:PEN) pay dividends? If so, how much?
Penumbra Inc(MEX:PEN) does not pay dividend.
Press Release
Articles on Penumbra Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers